WVP
DRMA icon

Worth Venture Partners’s Dermata Therapeutics DRMA Stock Holding History

Worth Venture Partners’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17
Closed -$180K – 139
2021
Q3 		$180K Buy
+17
New +$201K 0.08% 106

Other funds holding DRMA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCA
Sage Capital Advisors Sioux Falls, South Dakota $482M AUM 34.73% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return

Worth Venture Partners's DRMA Position: Q4 2021 in Review

Worth Venture Partners sold out of Dermata Therapeutics (DRMA) in Q4 2021, closing a stake of 17 shares — an estimated $180K sold.

Worth Venture Partners first reported a position in DRMA in Q3 2021 and held it in 1 quarter. The position peaked at $180K in Q3 2021. 8 funds tracked by Wall St. Rank hold DRMA as of Q4 2021.

  • Worth Venture Partners reported no remaining Dermata Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Worth Venture Partners sold 17 Dermata Therapeutics shares in Q4 2021, an estimated $180K.
  • Worth Venture Partners first reported a position in Dermata Therapeutics in Q3 2021 and held it in 1 quarter.
  • Worth Venture Partners's Dermata Therapeutics position peaked at $180K in Q3 2021.
  • 8 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q4 2021.

Based on Worth Venture Partners's 13F filing for Q4 2021, filed 14 Feb 2022.